Monocrotaline-induced pulmonary arterial hypertension: Time-course of injury and comparative evaluation of macitentan and Y-27632, a Rho kinase inhibitor
- 4 November 2019
- journal article
- research article
- Published by Elsevier BV in European Journal of Pharmacology
- Vol. 865, 172777
- https://doi.org/10.1016/j.ejphar.2019.172777
Abstract
No abstract availableKeywords
Funding Information
- Chiesi Farmaceutici
This publication has 34 references indexed in Scilit:
- Macitentan and Morbidity and Mortality in Pulmonary Arterial HypertensionNew England Journal of Medicine, 2013
- New mechanisms of pulmonary arterial hypertension: role of Ca2+signalingAmerican Journal of Physiology-Heart and Circulatory Physiology, 2012
- The monocrotaline model of pulmonary hypertension in perspectiveAmerican Journal of Physiology-Lung Cellular and Molecular Physiology, 2012
- Efficacy of aminaftone in a rat model of monocrotaline-induced pulmonary hypertensionEuropean Journal of Pharmacology, 2011
- Mechanisms of disease: pulmonary arterial hypertensionNature Reviews Cardiology, 2011
- Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertensionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Analysis of responses to the Rho-kinase inhibitor Y-27632 in the pulmonary and systemic vascular bed of the ratAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Improving Bioscience Research Reporting: The ARRIVE Guidelines for Reporting Animal ResearchPLoS Biology, 2010
- Acute Vasodilator Effect of Fasudil, a Rho-kinase Inhibitor, in Monocrotaline-Induced Pulmonary Hypertension in RatsJournal of Cardiovascular Pharmacology, 2007
- The effects of the Rho‐kinase inhibitor Y‐27632 on arachidonic acid‐, GTPγS‐, and phorbol ester‐induced Ca2+‐sensitization of smooth muscleFEBS Letters, 1998